Does New York Medicaid cover GLP-1s for weight loss?
Does New York Medicaid cover GLP-1s for weight loss?
New York Medicaid does not cover GLP-1s prescribed for weight loss. Coverage for type 2 diabetes, for Wegovy's cardiovascular indication and for Zepbound in moderate to severe sleep apnea is required of every state program regardless. So the practical question at a denial is rarely "does my state cover it" but "which indication am I being prescribed this under". On BMI: Over 40 — and only on the cardiovascular indication. Weight loss itself is excluded under section 1927(d)(2) of the Social Security Act. On what has to be tried or preferred first: Wegovy needs a confirmed cardiovascular-disease diagnosis, a BMI over 40 and documented participation in lifestyle modification. Those criteria are quoted from NYRx Drug Coverage Overview: Wegovy, read directly rather than summarized from an aggregator. Where the answer is no, the cheapest verified cash route on this site is $129 a month (compounded, not FDA approved; FDA warning letter). Last checked 2026-09-13.
What New York will approve, and on what
- On BMI
- Over 40 — and only on the cardiovascular indication. Weight loss itself is excluded under section 1927(d)(2) of the Social Security Act.
- What it takes
- Wegovy needs a confirmed cardiovascular-disease diagnosis, a BMI over 40 and documented participation in lifestyle modification.
NYRx also caps it at two treatment attempts per lifetime, which no other state on this page publishes.
Both tools fill from these criteria rather than from a template — a prior authorization for New York, or a letter appealing a denial. If the plan is not Medicaid, the 9 insurer and program pages cover a different set of rules.
Whatever New York decides about obesity, federal law still makes it cover a GLP-1 prescribed for type 2 diabetes, Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea — the exclusion is written against the use, not the drug. Which approval a weight-loss exclusion cannot reach, and what each label says.
If you end up paying cash
The cheapest verified GLP-1 routes — what you pay per month once titrated, not an introductory rate:
- Strut Health$129/moverified 2026-09-22compounded, not FDA approvedFDA warning letter
- Noom Med$249/moverified 2026-09-22compounded, not FDA approved
- Found$289/moverified 2026-09-22compounded, not FDA approved
Cheaper still, and a different class: Qsymia (phentermine/topiramate) at $75/mo — about 9.8% mean weight loss in its trial, against roughly 15 to 21% for the GLP-1s above. It is a real option and it is not a substitute.
The manufacturer programs cut the first fills further, and each one's catch is printed with it. Write the appeal first if you were refused — it costs nothing and the criteria above are what it has to answer.
Other states with criteria of their own
Source: NYRx Drug Coverage Overview: Wegovy , effective 2026-07-16. Read on 2026-09-13. Fee-for-service rules; a managed-care plan in New York can publish its own formulary and step edits. This is a record of what the payer publishes, not medical or legal advice.